Table 6 Multivariate analysis for CLDN6 expression in EAC and GAC
EAC | GAC | |||
|---|---|---|---|---|
Covariate | HR (95% CI) | p-value | HR (95% CI) | p-value |
Total cohort | ||||
Age | 1.02 (1.01–1.03) | 0.002 | 1.01 (0.99–1.02) | 0.28 |
pT | 1.32 (1.10–1.59) | 0.004 | 1.64 (1.30–2.07) | < 0.001 |
pN | 2.28 (1.70–3.06) | < 0.001 | 0.92 (0.61–1.37) | 0.66 |
L | 1.31 (1.00–1.70) | 0.046 | 1.92 (1.25–2.94) | 0.003 |
V | 0.95 (0.64–1.41) | 0.81 | 1.17 (0.74–1.88) | 0.50 |
Pn | 1.23 (0.91–1.66) | 0.17 | 0.90 (0.60–1.35) | 0.61 |
M | 2.0 (1.21–3.30) | 0.007 | 1.89 (1.23–2.92) | 0.004 |
Her2 status (ERBB) | 0.68 (0.42–1.11) | 0.12 | 1.41 (0.88–2.26) | 0.15 |
Neoadjuvant treatment | 1.21 (0.92–1.59) | 0.17 | 1.13 (0.79–1.62) | 0.50 |
CLDN6 expression | 1.75 (1.14–2.68) | 0.01 | 2.74 (0.98–7.69) | 0.028 |
Primary surgery cohort | ||||
Age | 1.03 (1.01–1.05) | 0.01 | 1.00 (0.98–1.02) | 0.92 |
pT | 1.52 (1.07–1.91) | 0.01 | 1.85 (1.21–2.11) | < 0.001 |
pN | 2.28 (1.28–1.95) | 0.01 | 0.86 (1.03–1.73) | 0.55 |
L | 1.85 (1.02–2.60) | 0.02 | 2.23 (0.98–2.63) | 0.003 |
V | 0.93 (0.56–1.62) | 0.82 | 1.06 (0.57–1.75) | 0.85 |
Pn | 0.97 (0.55–1.46) | 0.91 | 0.99 (0.72–1.84) | 0.97 |
M | 2.16 (1.34–4.90) | 0.045 | 1.86 (0.96–3.18) | 0.04 |
AJCC Grade | 1.27 (0.80–1.82) | 0.31 | 0.60 (0.41–0.89) | 0.01 |
Her2 status (ERBB) | 0.92 (0.79–2.02) | 0.82 | 1.33 (0.75 – 2.35) | 0.33 |
CLDN6 expression | 1.12 (0.4–3.18) | 0.82 | 4.21 (1.26–14.07) | 0.02 |
Neoadjuvant cohort | ||||
Age | 1.01 (0.99–1.02) | 0.42 | 1.02 (0.99–1.05) | 0.22 |
pT | 1.16 (0.90–1.50) | 0.24 | 1.54 (0.98–2.41) | 0.06 |
pN | 1.48 (1.26–1.72) | < 0.001 | 1.02 (0.46–2.27) | 0.96 |
L | 1.06 (0.75–1.50) | 0.74 | 2.17 (0.96–4.89) | 0.06 |
V | 0.86 (0.49–1.51) | 0.60 | 1.26 (0.51–3.07) | 0.62 |
Pn | 1.14 (0.77–1.68) | 0.5 | 0.69 (0.30–1.56) | 0.37 |
M | 2.9 (1.02–8.25) | 0.046 | 2.45 (1.17–5.15) | 0.02 |
Her2 status (ERBB) | 0.53 (0.27–1.04) | 0.06 | 1.31 (0.48–3.58) | 0.59 |
CLDN6 expression | 1.73 (1.03–2.91) | 0.037 | 2.80 (0.32–24.34) | 0.35 |